Helping You Build Wealth With Honest Research
Since 1996. Try Now

MEMBER'S LOGIN

MEMBER'S LOGINX

     
Invalid Username / Password
   
     
   
     
 
Invalid Captcha
   
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Indian stock markets open weak
Wed, 14 Sep 09:30 am

Most Asian stock markets have opened the day on a weak note. Stock markets in South Korea (down 2.7%) , Indonesia (down 1.9%) and Taiwan (down 1.3%) are leading the pack of losers. However, the markets in China (up 0.2%) are trading firm. The Indian stock market have opened the day on a weak note as well. Capital goods, power and banking stocks are leading the losses. However, stocks in the technology space are trading firm.

The BSE-Sensex is trading lower by around 55 points (0.3%), the NSE-Nifty is down by around 17 points (0.3%). While the BSE Mid Cap index has opened on a flat note, the BSE Small Cap index is up by 0.1%. The rupee is trading at 47.98 to the US dollar.

Engineering stocks have opened the day on a weak note with Bharat Heavy Electrical Ltd (BHEL), Larsen & Toubro (L&T), Havells India and Areva T&D leading the losses. Engineering and construction major L&T expects recovery of growth in its order book to come in the next few quarters of this year itself. The management had stated earlier that the order inflow was below their expectations. During the first quarter L&T received new orders of Rs 162 bn. This marked an increase of only 3.6% YoY for the quarter. However, the company has given a guidance of 15% growth in the order book for the full year. The company attributed the decrease in growth to the rising interest rates.

Pharma Stocks have opened the day on a firm note with Aurobindo Pharma, Ranbaxy Laboratories and Divi's Lab trading in the green. In order to be able to make the low-cost version of Lipitor, which is the world's largest selling drug, Ranbaxy Laboratories has commenced talks with Ind Swift, a Chandigarh-based Indian pharma company, for sourcing of raw materials. Ranbaxy is exploring various options to procure intermediate or final API (active pharmaceutical ingredient) atorvastatin. API is the basic chemical used in a drug. In the case of Ranbaxy's Lipitor, atorvastatin is the basic chemical. India's largest drug manufacturer has slated the launch of the drug in the US by 30 November, 2011.

For information on how to pick stocks that have the potential to deliver big returns, download our special report now!

View all commentaries | Archives

Read the latest Market Commentary


Equitymaster requests your view! Post a comment on "Indian stock markets open weak". Click here!

  
ABOUT EQUITYMASTER

Since 1996, Equitymaster has been the source for honest and credible opinions on investing in India. With solid research and in-depth analysis Equitymaster is dedicated towards making its readers- smarter, more confident and richer every day. Here's why hundreds of thousands of readers spread across more than 70 countries Trust Equitymaster.

PREMIUM PRODUCTS
QUICK LINKS
POPULAR TOPICS
TRENDING TOPICS
FREE NEWSLETTERS
EQUITYMASTER SUPPORTS
  • HelpYourNGO
  • You Tube
  • Linkedin
  • Twitter
  • Telegram
  • Google Play

Copyright © Equitymaster Agora Research Private Limited.

Whitelist | Refer | Terms | Privacy | Contact | About | Sitemap

Phone +91-9136015013

Equitymaster Agora Research Private Limited (Research Analyst)
SEBI (Research Analysts) Regulations 2014, Registration No. INH000000537.

103, Regent Chambers, Above Status Restaurant, Nariman Point, Mumbai - 400 021. India.
Telephone: +91-22-61434055. Email: info@equitymaster.com. Website: www.equitymaster.com.
CIN:U74999MH2007PTC175407

Name of the Compliance & Grievance Officer: Ms Sonal Ramachandran
Telephone: +91-22-61434003 | Email: compliance@equitymaster.com

LEGAL DISCLAIMER:
Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

All rights reserved. Any act of copying, reproducing or distributing this newsletter whether wholly or in part, for any purpose without the permission of Equitymaster is strictly prohibited and shall be deemed to be copyright infringement.

Equitymaster Agora Research Private Limited (Research Analyst) bearing Registration No. INH000000537 (hereinafter referred as 'Equitymaster') is an independent equity research Company. Equitymaster is not an Investment Adviser. Information herein should be regarded as a resource only and should be used at one's own risk. This is not an offer to sell or solicitation to buy any securities and Equitymaster will not be liable for any losses incurred or investment(s) made or decisions taken/or not taken based on the information provided herein. Information contained herein does not constitute investment advice or a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual subscribers. Before acting on any recommendation, subscribers should consider whether it is suitable for their particular circumstances and, if necessary, seek an independent professional advice. This is not directed for access or use by anyone in a country, especially, USA, Canada or the European Union countries, where such use or access is unlawful or which may subject Equitymaster or its affiliates to any registration or licensing requirement. All content and information is provided on an 'As Is' basis by Equitymaster. Information herein is believed to be reliable but Equitymaster does not warrant its completeness or accuracy and expressly disclaims all warranties and conditions of any kind, whether express or implied. Equitymaster may hold shares in the company/ies discussed herein. As a condition to accessing Equitymaster content and website, you agree to our Terms and Conditions of Use, available here. The performance data quoted represents past performance and does not guarantee future results.